Trial · NCT07884084
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in immunosuppressant drug blood levels | Immunosuppressant blood levels will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Cyclosporin A, tacrolimus and sirolimus will be measured using CMIA (Chemiluminescent Microparticle Immunoassay); everolimus using QMS (Quantitative Microsphere System); mycophenolic acid using CEDIA (Cloned Enzyme Donor Immunoassay); and prednisolone using ELISA (Enzyme-Linked Immunosorbent Assay). |
| Secondary | Changes in the blood levels of high-sensitivity C-reactive protein (hsCRP) | High-sensitivity C-reactive protein (hsCRP) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | High-sensitivity C-reactive protein (hsCRP) will be measured in mg/L using ELISA (Enzyme-Linked ImmunoSorbent Assay). |
| Secondary | Changes in the blood levels of interleukin-1β (IL-1β) | Interleukin-1β (IL-1β) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Interleukin-1β (IL-1β) will be measured in ng/L using ELISA (Enzyme-Linked ImmunoSorbent Assay). |
| Secondary | Changes in the blood levels of interleukin-6 (IL-6) | Interleukin-1β (IL-1β) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Interleukin-6 (IL-6) will be measured in ng/L using ELISA (Enzyme-Linked ImmunoSorbent Assay). |
| Secondary | Changes in the blood levels of tumor necrosis factor-α (TNF-α) | Tumor necrosis factor-α (TNF-α) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Tumor necrosis factor-α (TNF-α) will be measured in ng/L using ELISA (Enzyme-Linked ImmunoSorbent Assay). |
| Secondary | Changes in the blood urea nitrogen (BUN) | BUN will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Blood urea nitrogen (BUN) will be measured in mg/dL using a standard clinical chemistry analyzer. |
| Secondary | Changes in serum creatinine | Serum creatinine will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Serum creatinine will be measured in mg/dL using a standard clinical chemistry analyzer. |
| Secondary | Changes in Estimated Glomerular Filtration Rate (eGFR) | eGFR will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | eGFR will be measured in ml/min using a standard clinical chemistry analyzer. |
| Secondary | Body weight | Body weight will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period | Body weight in Kg will be measured using a professional medical scale. |
| Secondary | Body Mass Index (BMI) | Body Mass Index (BMI) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Body Mass Index (BMI) will be calculated as the ratio of body weight to the square of height. |
| Secondary | Waist circumference | Waist circumference will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Waist circumference in cm will be measured using a tape measure. |
| Secondary | Total body water | Total body water will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Total body water in Liters will be measured using Bioelectrical Impedance Analysis (BIA). |
| Secondary | Extracellular water | Extracellular water will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Extracellular water in Liters will be measured using Bioelectrical Impedance Analysis (BIA). |
| Secondary | Fat Mass (FM) | Fat Mass (FM) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Fat Mass (FM) in Kg will be measured using Bioelectrical Impedance Analysis (BIA). |
| Secondary | Fat Free Mass (FFM) | Fat Free Mass (FFM) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Fat Free Mass (FFM) in Kg will be measured using Bioelectrical Impedance Analysis (BIA). |
| Secondary | Phase Angle (PhA) | Phase Angle (PhA) will be measured at the following time points: • Day 0: baseline • Day 30: end of the first treatment period • Day 60: end of the washout period • Day 90: end of the second treatment period. | Phase Angle (PhA) will be calculated using the resistance and reactance values measured with BIA. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07884084/registered